284 related articles for article (PubMed ID: 10376237)
21. A naturalistic 6-year follow-up study of patients with panic disorder.
Lepola U; Koponen H; Leinonen E
Acta Psychiatr Scand; 1996 Mar; 93(3):181-3. PubMed ID: 8739663
[TBL] [Abstract][Full Text] [Related]
22. A multiple imputation strategy for clinical trials with truncation of patient data.
Lavori PW; Dawson R; Shera D
Stat Med; 1995 Sep; 14(17):1913-25. PubMed ID: 8532984
[TBL] [Abstract][Full Text] [Related]
23. Lactate-induced anxiety after imipramine and diazepam treatment.
Pohl R; Balon R; Berchou R; Lycaki H
Anxiety; 1994; 1(2):54-63. PubMed ID: 9160549
[TBL] [Abstract][Full Text] [Related]
24. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.
Charney DS; Woods SW; Goodman WK; Rifkin B; Kinch M; Aiken B; Quadrino LM; Heninger GR
J Clin Psychiatry; 1986 Dec; 47(12):580-6. PubMed ID: 3536889
[TBL] [Abstract][Full Text] [Related]
25. Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.
Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
Depress Anxiety; 2008; 25(8):E18-26. PubMed ID: 17960759
[TBL] [Abstract][Full Text] [Related]
26. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
Moylan S; Staples J; Ward SA; Rogerson J; Stein DJ; Berk M
J Clin Psychopharmacol; 2011 Oct; 31(5):647-52. PubMed ID: 21869686
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder.
Rimón R; Lepola U; Jolkkonen J; Halonen T; Riekkinen P
Biol Psychiatry; 1995 Dec; 38(11):737-41. PubMed ID: 8580226
[TBL] [Abstract][Full Text] [Related]
28. Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?
Maier W; Roth SM; Argyle N; Buller R; Lavori P; Brandon S; Benkert O
Eur Arch Psychiatry Clin Neurosci; 1991; 241(3):151-8. PubMed ID: 1790160
[TBL] [Abstract][Full Text] [Related]
29. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.
Modigh K; Westberg P; Eriksson E
J Clin Psychopharmacol; 1992 Aug; 12(4):251-61. PubMed ID: 1527228
[TBL] [Abstract][Full Text] [Related]
30. Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment.
Rosenberg R; Bech P; Mellergård M; Ottosson JO
Acta Psychiatr Scand Suppl; 1991; 365():39-45. PubMed ID: 1862733
[TBL] [Abstract][Full Text] [Related]
31. Adverse effects associated with the short-term treatment of panic disorder with imipramine, alprazolam or placebo.
Cassano GB; Toni C; Petracca A; Deltito J; Benkert O; Curtis G; Hippius H; Maier W; Shera D; Klerman G
Eur Neuropsychopharmacol; 1994 Mar; 4(1):47-53. PubMed ID: 8204996
[TBL] [Abstract][Full Text] [Related]
32. Pattern of placebo response in panic disorder.
Shear MK; Leon AC; Pollack MH; Rosenbaum JF; Keller MB
Psychopharmacol Bull; 1995; 31(2):273-8. PubMed ID: 7491379
[TBL] [Abstract][Full Text] [Related]
33. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder.
Woods SW; Nagy LM; Koleszar AS; Krystal JH; Heninger GR; Charney DS
J Clin Psychopharmacol; 1992 Feb; 12(1):32-8. PubMed ID: 1552038
[TBL] [Abstract][Full Text] [Related]
34. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
Greenblatt DJ; Harmatz JS; Shader RI
Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
[TBL] [Abstract][Full Text] [Related]
35. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure.
Cox BJ; Endler NS; Lee PS; Swinson RP
J Behav Ther Exp Psychiatry; 1992 Sep; 23(3):175-82. PubMed ID: 1487535
[TBL] [Abstract][Full Text] [Related]
36. A double-blind comparison of alprazolam vs. imipramine and placebo in the treatment of major depressive disorder.
Feighner JP; Meredith CH; Frost NR; Chammas S; Hendrickson G
Acta Psychiatr Scand; 1983 Oct; 68(4):223-33. PubMed ID: 6138925
[TBL] [Abstract][Full Text] [Related]
37. Discussion of "methodological controversies in the treatment of panic disorder".
Klein DF
Behav Res Ther; 1996; 34(11-12):849-53; discussion 855-63. PubMed ID: 8990537
[No Abstract] [Full Text] [Related]
38. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
[TBL] [Abstract][Full Text] [Related]
39. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.
Barlow DH; Gorman JM; Shear MK; Woods SW
JAMA; 2000 May; 283(19):2529-36. PubMed ID: 10815116
[TBL] [Abstract][Full Text] [Related]
40. Psychopathology of panic attacks in panic disorder.
Uhlenhuth EH; Leon AC; Matuzas W
J Affect Disord; 2006 May; 92(1):55-62. PubMed ID: 16448702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
